185 related articles for article (PubMed ID: 26986213)
1. Immune-Mediated Inflammation May Contribute to the Pathogenesis of Cardiovascular Disease in Mucopolysaccharidosis Type I.
Khalid O; Vera MU; Gordts PL; Ellinwood NM; Schwartz PH; Dickson PI; Esko JD; Wang RY
PLoS One; 2016; 11(3):e0150850. PubMed ID: 26986213
[TBL] [Abstract][Full Text] [Related]
2. Myoblast gene therapy in canine mucopolysaccharidosis. I: Abrogation by an immune response to alpha-L-iduronidase.
Shull RM; Lu X; McEntee MF; Bright RM; Pepper KA; Kohn DB
Hum Gene Ther; 1996 Aug; 7(13):1595-603. PubMed ID: 8864760
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of elastase activity in aorta in mucopolysaccharidosis I and VII dogs may be due to increased cytokine expression.
Metcalf JA; Linders B; Wu S; Bigg P; O'Donnell P; Sleeper MM; Whyte MP; Haskins M; Ponder KP
Mol Genet Metab; 2010 Apr; 99(4):396-407. PubMed ID: 20044292
[TBL] [Abstract][Full Text] [Related]
4. Gene therapy for canine alpha-L-iduronidase deficiency: in utero adoptive transfer of genetically corrected hematopoietic progenitors results in engraftment but not amelioration of disease.
Lutzko C; Omori F; Abrams-Ogg AC; Shull R; Li L; Lau K; Ruedy C; Nanji S; Gartley C; Dobson H; Foster R; Kruth S; Dubé ID
Hum Gene Ther; 1999 Jun; 10(9):1521-32. PubMed ID: 10395377
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of elastase proteins results in aortic dilatation in mucopolysaccharidosis I mice.
Ma X; Tittiger M; Knutsen RH; Kovacs A; Schaller L; Mecham RP; Ponder KP
Mol Genet Metab; 2008 Jul; 94(3):298-304. PubMed ID: 18479957
[TBL] [Abstract][Full Text] [Related]
6. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I.
Kakkis ED; McEntee MF; Schmidtchen A; Neufeld EF; Ward DA; Gompf RE; Kania S; Bedolla C; Chien SL; Shull RM
Biochem Mol Med; 1996 Aug; 58(2):156-67. PubMed ID: 8812735
[TBL] [Abstract][Full Text] [Related]
7. Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I.
Braunlin EA; Berry JM; Whitley CB
Am J Cardiol; 2006 Aug; 98(3):416-8. PubMed ID: 16860035
[TBL] [Abstract][Full Text] [Related]
8. Arterial pathology in canine mucopolysaccharidosis-I and response to therapy.
Lyons JA; Dickson PI; Wall JS; Passage MB; Ellinwood NM; Kakkis ED; McEntee MF
Lab Invest; 2011 May; 91(5):665-74. PubMed ID: 21383673
[TBL] [Abstract][Full Text] [Related]
9. Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-L-iduronidase gene.
Clarke LA; Russell CS; Pownall S; Warrington CL; Borowski A; Dimmick JE; Toone J; Jirik FR
Hum Mol Genet; 1997 Apr; 6(4):503-11. PubMed ID: 9097952
[TBL] [Abstract][Full Text] [Related]
10. Enzyme-replacement therapy in mucopolysaccharidosis I.
Kakkis ED; Muenzer J; Tiller GE; Waber L; Belmont J; Passage M; Izykowski B; Phillips J; Doroshow R; Walot I; Hoft R; Neufeld EF
N Engl J Med; 2001 Jan; 344(3):182-8. PubMed ID: 11172140
[TBL] [Abstract][Full Text] [Related]
11. Alpha-L-iduronidase and enzyme replacement therapy for mucopolysaccharidosis I.
Brooks DA
Expert Opin Biol Ther; 2002 Dec; 2(8):967-76. PubMed ID: 12517274
[TBL] [Abstract][Full Text] [Related]
12. 12 year follow up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I: the important role of early treatment.
Gabrielli O; Clarke LA; Ficcadenti A; Santoro L; Zampini L; Volpi N; Coppa GV
BMC Med Genet; 2016 Mar; 17():19. PubMed ID: 26965916
[TBL] [Abstract][Full Text] [Related]
13. Successful induction of immune tolerance to enzyme replacement therapy in canine mucopolysaccharidosis I.
Kakkis E; Lester T; Yang R; Tanaka C; Anand V; Lemontt J; Peinovich M; Passage M
Proc Natl Acad Sci U S A; 2004 Jan; 101(3):829-34. PubMed ID: 14715900
[TBL] [Abstract][Full Text] [Related]
14. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I.
Kakkis E; McEntee M; Vogler C; Le S; Levy B; Belichenko P; Mobley W; Dickson P; Hanson S; Passage M
Mol Genet Metab; 2004; 83(1-2):163-74. PubMed ID: 15464431
[TBL] [Abstract][Full Text] [Related]
15. Progressive heart disease in mucopolysaccharidosis type I mice may be mediated by increased cathepsin B activity.
Baldo G; Tavares AM; Gonzalez E; Poletto E; Mayer FQ; Matte UD; Giugliani R
Cardiovasc Pathol; 2017; 27():45-50. PubMed ID: 28104572
[TBL] [Abstract][Full Text] [Related]
16. Pentosan Polysulfate: Oral Versus Subcutaneous Injection in Mucopolysaccharidosis Type I Dogs.
Simonaro CM; Tomatsu S; Sikora T; Kubaski F; Frohbergh M; Guevara JM; Wang RY; Vera M; Kang JL; Smith LJ; Schuchman EH; Haskins ME
PLoS One; 2016; 11(4):e0153136. PubMed ID: 27064989
[TBL] [Abstract][Full Text] [Related]
17. Liver-directed neonatal gene therapy prevents cardiac, bone, ear, and eye disease in mucopolysaccharidosis I mice.
Liu Y; Xu L; Hennig AK; Kovacs A; Fu A; Chung S; Lee D; Wang B; Herati RS; Mosinger Ogilvie J; Cai SR; Parker Ponder K
Mol Ther; 2005 Jan; 11(1):35-47. PubMed ID: 15585404
[TBL] [Abstract][Full Text] [Related]
18. Unexpected coronary artery findings in mucopolysaccharidosis. Report of four cases and literature review.
Braunlin E; Orchard PJ; Whitley CB; Schroeder L; Reed RC; Manivel JC
Cardiovasc Pathol; 2014; 23(3):145-51. PubMed ID: 24508139
[TBL] [Abstract][Full Text] [Related]
19. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.
Jameson E; Jones S; Remmington T
Cochrane Database Syst Rev; 2016 Apr; 4():CD009354. PubMed ID: 27033167
[TBL] [Abstract][Full Text] [Related]
20. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.
Jameson E; Jones S; Wraith JE
Cochrane Database Syst Rev; 2013 Nov; (11):CD009354. PubMed ID: 24257962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
